Cochrane · systematic review · CD011680
Interventions for necrotizing soft tissue infections in adults
Hua, C, Bosc, R, Sbidian, E, et al. · Cochrane Database of Systematic Reviews · 2018 · Cochrane Library
SkinAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
12
current version
GRADE rated
8
No studies
4
Included studies
NR
No studies 4 · 33.3%Ungraded 0 · 0%Very low 5 · 41.7%Low 3 · 25%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Moxifloxacin compared to amoxicillin‐clavulanate for NSTI
Population: NSTI
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Mortality Moxifloxacin vs amoxicillin‐clavulanate | RR 3 [0.39, 23.07] | 1 study · 54 participants | Very low Downgraded: risk of bias, imprecision, indirectness |
Serious adverse events (SAE) Moxifloxacin vs amoxicillin‐clavulanate | RR 0.63 [0.3, 1.31] | 1 study · 54 participants | Very low Downgraded: risk of bias, imprecision, indirectness |
Survival time Moxifloxacin vs amoxicillin‐clavulanate | no estimate extracted | 1 study · 54 participants | Very low Downgraded: risk of bias, imprecision, indirectness |
Assessment of long‐term morbidity Moxifloxacin vs amoxicillin‐clavulanate | no estimate extracted | NR | No studies |
AB103 compared to placebo for NSTI
Population: NSTI
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Mortality AB103 vs placebo | RR 0.34 [0.05, 2.16] | 1 study · 43 participants | Very low Downgraded: risk of bias, imprecision, indirectness |
Serious adverse events (SAE) AB103 vs placebo | RR 1.49 [0.52, 4.27] | 1 study · 43 participants | Very low Downgraded: risk of bias, imprecision, indirectness |
Survival time AB103 vs placebo | no estimate extracted | NR | No studies |
Assessment of long‐term morbidity AB103 vs placebo | no estimate extracted | NR | No studies |
Intravenous immunoglobulin compared to placebo for NSTI
Population: NSTI
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Mortality Intravenous immunoglobulin vs placebo | RR 1.17 [0.42, 3.23] | 1 study · 100 participants | Low Downgraded: risk of bias, indirectness |
Serious adverse events (SAE) Intravenous immunoglobulin vs placebo | RR 0.73 [0.32, 1.65] | 1 study · 100 participants | Low Downgraded: risk of bias, indirectness |
Survival time Intravenous immunoglobulin vs placebo | no estimate extracted | 1 study · 100 participants | Low Downgraded: risk of bias, indirectness |
Assessment of long‐term morbidity Intravenous immunoglobulin vs placebo | no estimate extracted | NR | No studies |